| Advice You |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Change Management > Leading Change; It's 24-7 |
|
Advice You - Leading Change; It's 24-7
Change has been occurring since before the beginning of man, so it is a fair bet that it will not stop soon. Whether organisations like it or not, they will change. External influences change the constraints an organisation has, According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product the expectations their stakeholders place upon them and change the values and capabilities of their people. What separates organisations from one another is how they deal with change. Some react to change along a conservative lin ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in , waiting until the last moment to adapt to change. They resist change at every turn, believing in the intrinsic value of "tradition". They tend to be backward looking, remembering the "good old days" and ignoring the here and now lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. They do gain some advantage in being able to learn from others mistakes and successes. Unfortunately for them, if they face competition change may come too late to survive. If they have a monopoly then it is time to pity their here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe poor customers for having to suffer products and services befitting the era of their parents or grandparents. If they are a government entity then pity the poor country as it loses competitiveness in an ever freer global trading e d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro vironment. Some go along with the flow, not resisting change but not embracing it. They take a somewhat conservative line, sensing their operating environment so as not to fall too far behind the change and organising themselves ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc o ensure that the change has a low impact on their organisation. Others though, embrace change, sensing that the time is right to make bold changes and chase audacious goals. With a combination of internal drive, common goals and easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi inspirational leadership these organisations add to the pressure other organisations feel to make change happen also. The role of leaders in an organisation that embraces change is paramount. The stresses and strains placed on a nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically leader are immense and usually underestimated. The impact of this underestimation is that many times leaders fail. They do not have the focus, the sense of, and ability to create order, the tolerance for uncertainty, the human to and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ ch and the sheer stamina required to see the change through. Leading change requires focus on the end game. It's like staring in a candle when all that can be seen is the bright burning flame of the end result. The end result mus ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi be able to be communicated simply and readily understood. If it cannot be expressed in a single sentence then it is unlikely to be understood. The road to the end result must be clear. It does not have to be expressed in a level ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a of detail that requires a two thousand line Microsoft Project plan. What must be clear are the next steps and the means by which the following steps will be determined. The end game and the next steps for sixty to ninety days mu dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod t be clear. Each individual in the organisation can then contribute to either the next sixty to ninety days of action or further planning to get closer to the end game. The role of a leader is not only to arrange the resources to cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin plan and execute the next steps but to provide comfort to others who are unable to cope with the ambiguity of a change project. Ambiguity always arises in a change project as change is as much about people's behaviour as it is ab tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen out process and policy. The very starting of a change project will create a change in behaviour from fear or anxiousness or eagerness. The behavioural impact of changes made will always therefore be ambiguous and changes will inev t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel tably be made to well thought through plans which did not work. Most people cannot cope with ambiguity. The leader needs to refocus the team and provide the emotional surety that solutions can be found. Leaders of change need to ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust be able to demonstrate a wide range of styles during a change programme. Autocratic and democratic styles will work during different phases of change as will being a facilitator or a coach, but at all times a leader must show a hu y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products man touch. Leaders must be able to show that even in making tough decisions they understand the impact on people. That is, not to shy away from the decision, but to show empathy. Leaders have to show this human touch and not expe . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de t words to be enough. Leaders of change are on show all the time. They must remain focused, positive and encouraging. Even the slightest lapse can put a project back months or in some cases be terminal. It takes great stamina to elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ead significant change. Leading change is tough and lonely but also rewarding as true leaders of change will witness the development of other leaders following in their footsteps. When that happens, it is worth being on show 24x7 tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:What are the Effective Ways To Reduce Your Business Costs Increase Your Income through International Trade Collection of Delhi Manufacturers - I
|